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Our objective was to examine the usefulness of the Ki67 proliferation index as a prognostic marker in patients with medullary thyroid
carcinoma (MTC). It is difficult to predict the prognosis of MTC by using conventional prognostic factors. Immunocytochemical
analysis of tumour proliferation has been used as a prognostic tool in some tumours, but only rarely in MTC. In all, 71 tumours from
36 patients were investigated, by using a semiautomatic image analysis programme. On average 10000 nuclear profiles were counted
per tumour, and the percentage of tumour cells expressing the proliferation marker, Ki67, was calculated. Primary tumours that had
metastasised had higher Ki67 indices than primary tumours that had not metastasised. Recurrent lymph node metastasis had higher
Ki67 indices than the primary tumours. By using a Poisson model, it was possible to estimate the median survival time for individual
patients if the Ki67 index for the primary tumour and the age at surgery were known. The higher the Ki67 index and the age at
operation were, the shorter was the survival. Estimating the median survival of individual patients will be of help for planning the
patients’ life and postoperative follow-up and treatment.
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Medullary thyroid carcinoma (MTC) is derived from the calcitonin-
producing C cells of the thyroid. Determination of serum calcitonin
concentrations is used to diagnose and follow patients with MTC
(Wells et al, 1978; Tisell et al, 1996). In the TNM classification of
thyroid tumours, papillary carcinoma with lymph node metastasis
in young patients is classified as a stage I disease. A similar extent
of MTC has a worse impact on survival and is classified as a stage
III disease (The Committee on TNM classification UICC, 1992).
Medullary thyroid carcinoma patients with lymph node metastasis
often have persistent disease after the operation. In one-third of
such patients, meticulous neck dissection led to normalisation of
the serum calcitonin concentrations (Tisell et al, 1986; Moley et al,
1993). The prognosis of MTC patients is difficult to predict using
conventional prognostic factors, for example, age, sex, stage,
histopathological growth pattern, ploidy or biochemical tumour
markers (Tisell et al, 1996). Half of the MTC tumours can be
localised with octreotide scintigraphy due to their expression of
somatostatin receptors. The visualised tumours grew more rapidly
and aggressively than nonvisualised lesions, suggesting that
octreotide scintigraphy may be used as a prognostic tool (Tisell
et al,1997). Immunocytochemical analysis of tumour proliferation
has become an important tool for the assessment of tumour
aggressiveness and prognosis (Tubiana and Courdi, 1989). The aim
of the present study was to evaluate tumour proliferation, measured
by Ki67, as a prognostic marker for MTC. For this, Ki67 indices of
primary tumours were related to the clinical course of the MTC
patients. The possible presence of mutation of the p53 gene was
also investigated.
MATERIAL AND METHODS
Patients
Paraffin blocks with tumour tissue from 36 patients, 20 females and
16 males were retrieved. Each patient had at least one operation for
MTC at the Sahlgrenska University Hospital. In all, 23 patients had
sporadic MTC, 12 had MEN 2A and one a MEN 2B syndrome. The
mean age (s.d.) at operation was 45 (15) years (median 44years).
The tumours were classified according to the TNM classification
(The Committee on TNM classification UICC, 1992).Tumour stage
at initial operation was: stage I, two patients; stage II, six patients;
stage III, 22 patients; and stage IV, six patients. The follow-up
ended in March 2000. At diagnosis, six patients had distant
metastasis. During follow-up 11 additional patients got distant
metastasis. In all, 13 of the patients with distant metastasis died of
MTC at a mean (s.d.) of 8 (7) years (median 7 years) after diagnosis,
two patients died of unrelated causes after 17 years. A total of 21
patients were alive at follow-up at a mean of 20 (9) years (median
18 years) after the operation. All survivors were asymptomatic, but
four had distant metastasis. The postoperative observation time for
the total series was 15 (10) years (median 15 years). Individual
clinical features of the 36 patients can be found in Table 1.
In all, 71 tumour specimens were investigated, 36 primary
tumours, 21 primary lymph node metastasis and 14 recurrent lymph
node metastasis. The mean (s.d.) (median) of the Ki67 indices for all
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the primary tumours, primary metastasis and recurrent metastasis
were 0.74% (0.96) (median 0.41%), 1.35% (1.49) (median 0.85%)
and 4.73% (6.39) (median 1.65%), respectively. In 12 cases, tumour
tissue was available from primary tumours, primary metastasis and
also from recurrent metastasis. This subset of patients was tested for
within-subject differences between the Ki67 indices of the three
kinds of tumours. In another analysis, the Ki67 values of the 28
primary tumours that had metastasised were compared to those of
the eight tumours that had not metastasised.
Therapy
Since 1972, the operation involved a total thyroidectomy and a
meticulous central lymph node dissection. Lateral lymph node
dissections, on one or both sides were carried out in cases with
palpable primary tumours or palpable lymph nodes in the central or
lateral neck. Patients cared for at our hospital, after less radical
operations performed before 1972, or after incomplete surgery
elsewhere, had completion thyroidectomies with central lymph node
dissections. In case of tumour recurrence repeat neck operations
were performed. After the operations, the patients were followed
annually at our outpatient clinic. Patients with terminal disease were
followed more often. The close surveillance of the patients
guaranteed that the causes of death could be verified in all cases.
Immunocytochemistry
Paraffin blocks of tumour tissue were retrieved from the
Department of Pathology, Sahlgrenska University Hospital. The
tissues had been routinely fixed in neutral-buffered formalin for
1–2 days and embedded in paraffin wax. Sections (3–4mm) from
primary tumours and lymph node metastasis were placed on
positively charged glass slides, deparaffinised and rehydrated.
Antigens were retrieved by microwave treatment in citrate buffer
(10mM citrate, pH 6.0) twice for 5min. In order to assure even
staining of tissue sections, the incubation of sections was
performed in a Techmate 500 immunostainer under identical
conditions. Incubation with primary antibodies was carried out
for 25min, followed by biotinylated goat anti-mouse antibodies
(LSAB, Dako), streptavidin–HRP and diaminobenzidine.
After counter staining in Mayer’s haematoxylin, sections were
dehydrated and mounted. All antisera were diluted in antibody
diluent (Tris-buffer pH 7.2, containing 15mM sodium azide and
protein; Dako). The following primary antibodies were used:
mouse anti-Ki67 monoclonal antibody (clone MIB-1; Immuno-
tech) and mouse anti-p53 monoclonal antibodies (clone PAb1801
and DO-7; Dako). As negative controls served sections incubated
identically, except for the primary antibody that was replaced by
normal mouse IgG. As positive controls served sections of normal
tissues (lymph node for Ki67) or tumour tissues (colorectal cancer
for p53).
Table 1 Clinical features of the 36 MTC patients
No. Sex MTC type
Ki67% primary
tumour
Tumour diameter
(mm)
Tumour stage
pTNM
Age at operation
(years)
Postoperative
survival (years)
Status at
follow-up
1 F H* 0.01 5 III 24.89 14.06 Alive
2 M S 0.03 18 III 59.16 17.26 Died O.C.w
3 F H 0.05 60 II 35.14 49.11 Alive
4 M S 0.09 27 II 43.75 26.13 Alive
5 M S 0.19 50 III 49.90 17.25 Died O.C.w
6 F S 0.20 10 III 41.41 26.91 Alive
7 F S 0.23 45 IV 29.30 19.19 Died MTC
8 M H 0.24 55 II 31.95 14.23 Alive
9 M H 0.24 4 I 18.73 22.69 Alive
10 F S 0.26 5 I 48.61 18.18 Alive
11 F S 0.26 22 III 74.19 8.61 Died MTC
12 F S 0.27 13 III 60.84 29.61 Alive
13 F S 0.30 20 II 55.29 18.60 Alive
14 F H 0.31 5 III 31.55 16.08 Alive
15 F S 0.32 40 III 38.65 24.40 Alive
16 M H 0.33 60 III 41.84 6.49 Died MTC
17 M H 0.34 20 IV 59.32 2.65 Died MTC
18 M H 0.36 47 III 30.06 22.60 Died MTC
19 F H 0.46 13 III 42.38 12.77 Alive
20 F S 0.46 40 IV 30.84 5.07 Died MTC
21 F H 0.49 30 II 22.19 10.61 Alive
22 F H 0.56 25 III 38.13 13.06 Alive
23 F S 0.59 42 III 50.64 9.54 Died MTC
24 F S 0.62 45 II 66.43 6.95 Died MTC
25 M S 0.63 45 III 38.41 20.07 Alive
26 F H 0.73 15 III 65.38 10.11 Alive
27 F H 0.75 4 III 18.58 16.30 Alive
28 M S 0.77 40 III 47.56 10.05 Died MTC
29 F S 0.85 25 III 39.81 19.71 Alive
30 M S 0.88 12 III 63.84 12.38 Alive
31 M S 1.12 50 III 43.45 25.32 Alive
32 F S 1.27 47 III 62.49 16.6 Alive
33 M S 1.84 70 III 59.16 7.65 Died MTC
34 M S 2.58 Missing IV 56.78 1.79 Died MTC
35 M S 3.51 37 IV 64.27 1.09 Died MTC
36 M S 4.5 50 IV 47.72 0.64 Died MTC
H¼hereditary; MTC, S¼sporadic MTC; died O.C.
w¼died of other causes than MTC; pTNM¼postsurgical histopathological classsification; T¼tumour; N¼regional lymph
node metastasis; m¼distant metastasis.
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In order to estimate the growth rate of tumours, the percentage of
tumour cells expressing the proliferation marker Ki67 was
measured. A proliferation index was calculated for each tumour
lesion by counting the total number of tumour cell nuclear profiles
and the number of Ki67-positive nuclear profiles in randomly and
systematically selected fields. The first field in each tumour lesion
was selected randomly, and the following fields were sampled
systematically using a mesh. On average 10000 nuclear profiles
were counted per tumour lesion. Counting was performed using a
semiautomatic image analysis programme (IBAS).
Statistics
The Mann–Whitney test was used to compare the Ki67 values of
the primary tumours that had not metastasised (stages I and II)
with those that had metastasised (stages III and IV). The Friedman
test followed by Dunn’s multiple comparison post-test was used to
investigate within-subject differences between Ki67 values of
primary tumours and primary and recurrent metastasis of the 12
patients who had tumour tissue available from all the three kinds
of tumour lesions.
Survival analysis For the survival analysis, the following
variables were noted for each patient: Ki67 index of the primary
tumour, age at operation, survival time after the operation, death
of MTC or not (Table 1). A Poisson model (Breslow and Day, 1987)
was applied to estimate the hazard function of death from MTC.
The hazard function was of the form exp (b0þb1 time since
operationþb2 current ageþb3 Ki67) Also a model including
interaction between time and Ki67 was studied. For the derivation
of the cause-specific median survival time see the addendum. If the
age at operation and the Ki67 index are known, the formula of the
last line of the addendum can be used to calculate the median
survivals for individual patients.
In a Poisson regression, the variables tumour size, sex, type of
tumour and tumour stage were included one at a time together with
the variables Ki67 and age to find out if any of the four first
mentioned variables had any significant importance for death of
MTC. For these calculations, tumour size was represented by the
largest tumour diameter, type of tumour was sporadic or hereditary
tumours, stage was stages I and II or stage III and IV. The variables
for each patient can be found in Table 1. The two patients who died
of unrelated causes were censored at the date of death and the
patients alive at the end of the study were censored at that time.
RESULTS
The subset of 12 patients who had tumour tissue available from
primary tumours, primary metastasis and recurrent metastasis
could be used to test for within-subject differences between the
three kinds of tumour lesions. In this subset of patients, the Ki67
values of the primary tumours, the primary metastasis and the
recurrent metastasis were 0.80% (0.74) (median 0.53%), 1.56%
(1.72) (median 1.11%) and 4.62% (6.40) (median 1.65%),
respectively. The higher value for the recurrent metastasis vs the
primary tumours was significant (Po0.01).
Primary tumours that had metastasised, stages III and IV, had
higher Ki67 indices, 0.87% (1.05) (0.51%) than primary tumours
without metastasis, stages I and II, 0.29% (0.19) (0.25%) (Po0.05).
Survival analysis
The b-coefficients determining the hazard function and the
median postoperative survival time are found in Table 2. The
estimated median cause-specific survival times, at three ages, for
five different Ki67 values, are presented in Table 3. This table
shows that the estimated median survival time will be reduced with
higher ages at surgery and with higher Ki67 indices. Median
survival times for other values of age and Ki67 can be calculated by
using the formula on the last line of the addendum.
Figure 1 shows an example of three calculated curves of median
survival, where the age at operation is 45 years. In contrast to the
curves of the Poisson regressions is the curve of the Cox regression
a step function, which is a weakness when applied to individual
patients. The variables entered in the three regression curves were
original data from the studied population.
When including the variables sex, tumour size, tumour type and
tumour stage, one at a time together with Ki67 and age, in a
Poisson regression none of the four first mentioned variables had
any significant importance for death of tumour. Closest to
significance was size with P¼0.1710. The calculation of median
survival depending on Ki67 was not affected by the new variables.
p53 labelling
Immunostaining with two different antibodies against p53 failed to
label any of the investigated tumours, while control tissues
(colorectal carcinoma) were positive. This is in accordance with
previous studies showing the absence of p53 mutations in MTC
(Yana et al, 1992; Herfarth et al, 1997).
DISCUSSION
Several studies have investigated the usefulness of proliferation
markers as prognostic tools in human neoplasm, for example, soft-
tissue tumours, prostate, ovarian and lung carcinoma (Raymond
et al, 1988; Pence et al, 1993; Drobnjak et al, 1994; Kerns et al,
1994). Immunocytochemical detection of the nuclear proliferation
antigen Ki67 with MIB-1 monoclonal antibody can be used to
Table 2 b-coefficients for calculating the hazard function and the
estimated median survival time
Variable b-coefficients s.e.
Two-tailed
P-value
Constant  5.9290 1.3405
Time since operation (years)  0.0199 0.0436 P40.30
Current age (years) 0.0285 0.0224 P¼0.22
Ki67% 1.1347 0.2437 Po0.001
Table 3 The estimated postoperative median survival for five Ki67 values
at three ages
Ki67 index of primary
MTC tumours
Age at operation
(years)
Cause-specific, median
survival (years)
0.6 35 40.6
0.7 35 36.8
1.0 35 27.4
2.0 35 9.5
4.5 35 0.6
0.6 45 31.8
0.7 45 28.2
1.0 45 21.2
2.0 45 7.2
4.5 45 0.4
0.6 55 24.7
0.7 55 22.2
1.0 55 16.3
2.0 55 5.5
4.5 55 0.3
Note that the higher the Ki67 index of the primary tumour and age at operation
were, the shorter was the estimated postoperative survival.
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method has been used also in endocrine tumours. For thyroid
tumours, it has been shown that anaplastic tumours have higher
Ki67 indices than well-differentiated thyroid tumours (Carr et al,
1993), and that Hu ¨rthle cell carcinomas of the thyroid have higher
Ki67 indices than benign Hu ¨rthle cell adenomas (Erickson et al,
2000). There are few studies about Ki67 indices in MTC, and these
studies include few patients (Rigaud and Bogomoletz, 1991; Carr
et al, 1993; Wang et al, 1996). In the present long-term follow-up
study, we examined MTC tumour specimens from 36 patients to
find out if the level of Ki67 expression was related to the level of
malignancy. According to the TNM system, MTC tumours without
metastasis are classified as stages I and II disease, while tumours
with metastasis are classified as stages III and IV disease.
Significantly higher Ki67 indices were found in primary tumours
that had metastasised than in primary tumours without metastasis.
It was also found that recurrent metastasis had higher Ki67 indices
than primary tumours, which is in agreement with the observation
that in papillary thyroid cancer the proportion of proliferating cells
increased with each recurrence (Ozaki et al, 1999).
According to DeLellis (1995), the Ki67 index cannot be used to
judge the malignancy of individual endocrine tumours, but this
marker may be helpful in identifying subsets of tumours that will
follow an aggressive course. To explore whether the Ki67 index
could predict the cause-specific postoperative survival in indivi-
dual patients, we used a Poisson model to analyse the data
(Breslow and Day, 1987) and a formula was derived that can be
used to estimate the cause-specific median survival time for
individual patients, if the Ki67 index and age at surgery are known.
Estimated individual survival times were found to be reduced with
higher Ki67 indices and higher age at surgery. With the Poisson
model, the estimated median survival can be obtained for every
age and for every value of the Ki67 index. The median survival can
also be calculated with the help of a Cox model, but compared to
the Poisson model it is less appropriate since the resulting function
of the Cox model is a step function, which cannot be used to obtain
the median survival for every value of the Ki67 index (cf Figure 1).
When including the variables tumour size, sex, type of tumour
(sporadic or hereditary) and tumour stage, one at a time together
with Ki67 and age, in a Poisson regression none of the four first
mentioned variables had any significant importance for death of
MTC. The calculation of median survival depending on Ki67 was
not affected by the new variables. This shows that the Ki67 index is
a very suitable prognostic marker for MTC.
Estimating the median survival of individual patients will be of
help for planning the patients’ life and postoperative follow-up and
treatment.
ADDENDUM
Derivation of the median survival time T.
Let h(t) be the hazard function of death.
Then expð 
R T
0
hðtÞdt ¼ 0:5
Thus
R T
0
hðtÞdt ¼  logð0:5Þ:
Let age0 be the age at operation. Then the current age t years
after operation is age0þt.
Hence, the above equality can be written:
Z T
0
expðb0 þ b1t þ b2ðage0 þ tÞþb3Ki67Þdt ¼ logð0:5Þ:
Then we have
R T
0
expððb1 þ b2ÞtÞdt ¼ logð0:5Þ expð ðb0 þ b2
age0 þ b3Ki67ÞÞ:
Then the integral can be calculated and thus
ðexpððb1 þ b2ÞTÞ 1Þ=ðb1 þ b2Þ¼  logð0:5Þ expð ðb0 þ b2age0
þ b3Ki67ÞÞ:
Finally, T ¼ log½ð logð0:5Þ expð ðb0 þ b2 age0 þ b3Ki67ÞÞ 
ðb1 þ b2ÞÞ þ 1 =ðb1 þ b2Þ:
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